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Abstract
New evidence is given to support the hypothesis that the tributyltin compound (TBT) is an uncoupler of the oxidative
phosphorylation in mitochondria. By means of an Arrhenius plot, it has been demonstrated that the transport kinetic of the TBT
compound in mitochondria behaves in a manner which is similar to that obtained using classical uncouplers. The break point at
17 8C observed in the Arrhenius plot is interpreted as due to a phase change in the lipidic bilayer, since the TBT compound, like
uncouplers and mobile carriers, is sensitive to the phospholipidic phase change. Therefore, we can confirm our previous hypothesis
that, as TBT is an uncoupler it, like uncouplers, crosses the biological membranes by means of an electrophoretic mechanism. An
understanding of this behaviour is essential when an explanation of the neurotoxicity of TBT is required.
# 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The toxicity of trialkyltin (TAT) compounds in
humans and whole organisms has already been largely
documented [1/12]. Many ‘in vitro’ experiments have
been performed in cells and in subcellular structures in
order to find the molecular mechanism which is
responsible for this toxicity in animals. In particular,
the interactions of TAT compounds with mitochondria,
which are the energy source for the cell, have been
widely studied [3/11]. All the results indicate that the
TAT compounds inhibit ATP synthesis in mitochon-
dria, but researchers do not agree about the mechanism
responsible for the inhibition of the ATP synthesis. In
particular, Aldridge et al. [3,4,6,7], suggest that TAT
compounds behave as Cl/OH exchangers in mito-
chondria, since they enter the membrane as alkyl3SnCl
and are extruded as alkyl3SnOH. The consequence of
this cyclic mechanism is the collapse of the internal pH
in mitochondria. More recently, Bragadin et al. [10/12]
have proposed that the TAT compounds enter the
mitochondria as alkyl3Sn
 aquo-cations and are ex-
truded as alkyl3SnOH electroneutral compounds. The
balance of this cyclic mechanism is the transport, at any
cycle, of a proton through the membrane, with a
consequent DpH and DF collapse in the membrane.
Since DpH and DF are the protonmotive force [13]
which drives the ATP synthesis, this mechanism, which
is similar to that induced by uncouplers (i.e. chemical
compounds such as 2,4 dinitrophenol or FCCP which
enhance proton permeability), could explain the ATP
synthesis inhibition induced by TAT compounds. This
last mechanism, however, could explain not only the
toxicity, but, in particular, the neurotoxicity of TAT
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compounds. In fact, an uncoupling mechanism ‘neces-
sarily’ implies a step in which the uncoupler (which must
be a weak acid) crosses the membrane as a charged ion
[13]; in the case of TAT compounds, the charged ion is
the cation alkyl3Sn
 and the driving force for the
transport of the cation is the negative-inside potential.
Since nerve cells possess the highest (negative-inside)
potential, and since the uptake rate depends exponen-
tially on the applied potential [14], as already suggested
by Bragadin et al. [10/12], this fact could explain why
nerve cells are the preferential target for TAT com-
pounds.
In this paper we give new evidence regarding this
mechanism, resulting from the study of the transport
mechanism of the tributyltin (TBT) compound at
different temperatures. In fact, the aim of the paper is
to confirm the uncoupler-like behaviour of TBT and to
demonstrate that this compound crosses the membrane
through the lipidic bilayer, in the same way as uncou-
plers, which are mobile carriers, and not by means of
physiological carriers. These letters are not mobile
carriers, but proteic pores (for example, the Ca2
carrier, [15,16]) which connects the inside and outside
aqueous phases in biological vesicles. This clarification
is important since, if the transport of TBT occurs
through a specific proteic pore, it becomes essential to
find the particular protein present only in the nerve cells
as a (specific) carrier of the TBT compound, in order to
explain the neuroselectivity. On the contrary, if the
transport mechanism occurs through the phospholipidic
bilayer (as in the case of mobile carriers), this does not
imply the presence of any particular carrier-protein in
the nerve cells, since the phospholipidic bilayer has the
same physical characteristics in all biological mem-
branes.
2. Materials and methods
Mitochondria extracted from rat liver were prepared
following the usual procedures [15]. The mitochondrial
protein concentration was determined using the Lowry
et al. method [17]. The potassium efflux was determined
using a (Beckman) potassium selective electrode stored
in a thermostated glass vessel with magnetic stirring.
The recording apparatus was a Radiometer pH meter
connected to a Texas recorder.
All the chemicals were of the highest purity commer-
cially available. The valinomycin and FCCP (carbonyl-
cyanide p -trifluoromethoxyphenulhydrazone) were
obtained from Sigma. Tributyltin chloride was obtained
from Aldrich.
The cyclosporin A was kindly donated by Professor P.
Bernardi.
3. Results and discussion
The mitochondrial matrix contains about 0.1 M
potassium. If non-respiring mitochondria are resus-
pended in a potassium-free medium (or in a medium
with a low potassium concentration), K tends to efflux
from the matrix to the resuspending medium, providing
the presence of the potassium carrier, valinomycin, since
the mitochondrial membrane is not permeable to the
potassium ion (and to the protons). However, the K
efflux is very limited, since it gives rise to an equivalent
negative-inside potential gradient (DF) (Fig. 1(a)). As
DF is an oppositive force, the extent of this force can
easily be calculated and measured from the K gradient
DF/RT/nFLog[K]in/[K]out.
A massive and complete K efflux occurs if a
permeant positive counterion is added to the mitochon-
drial suspension. Fig. 1(b) shows that the addition of
Ca2 which enters the mitochondria through a selective
channel [15,16] (Fig. 1(a)), induces a fast K efflux since
the positive charge of Ca2 enters and neutralises the
negative-inside potential. Analogously, if an uncoupler
(FCCP) which permeates the membrane to the protons,
is added, it induces a K release (Fig. 1(b)). In this case,
the efflux of K is due to the same mechanism. This
experimental condition (shown in Fig. 1) allows for a
study of the transport kinetics of K (by means of
valinomycin) or H (by means of uncouplers) if the
respective transport is the rate limiting step in the whole
kinetic. If valinomycin is the rate limiting step (i.e., a low
valinomycin concentration and a high uncoupler con-
centration), the K efflux measured, using a selective
K electrode, indicates the rate of transport of K by
means of valinomycin. If the proton transport is the rate
limiting step (i.e., a low uncoupler concentration and a
high valinomycin concentration), the K efflux mon-
itored by means of the K electrode is a measure of the
proton transport through the membrane.
Therefore, as discussed above, in order to measure the
potassium transport, it is necessary to proceed using low
valinomycin concentrations and a large amount of the
uncoupler. As a means of verifying whether the potas-
sium transport can be measured effectively under these
conditions, a further measurement is performed after
increasing the concentration of valinomycin. If the rate
of K efflux (measured as the initial rate, see Fig. 1b) is
enhanced, this confirms that the valinomycin concentra-
tion is responsible for the limiting step in the condition
under observation.
Analogously, in order to ensure that the proton
transport is the limiting step under a particular experi-
mental condition, it is sufficient to perform a successive
measurement with a higher concentration of uncoupler.
If the rate of K efflux is enhanced, this demonstrates
that the kinetics of the proton transport have been
observed.
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This procedure has been previously followed in order
to study, by means of an Arrhenius plot, the transport
kinetics of the mobile carriers (e.g. DNP, valinomycin)
and the proteic pores such as the calcium carrier and
gramycidin [15,16]. The results indicate that all pore
carriers give an Arrhenius plot with a low slope, which
corresponds to a low activation energy in the transport
system, while all mobile carriers show two activation
energies with a break point at 17 8C [15,16]. As the
break point in the Arrhenius plot is the same concerning
all mobile carriers, this was interpreted as due to a phase
change in the lipidic bilayer. The failure of the break
point observed in the Ca2 and gramycidin transport
was explained by the fact that a proteic pore is not
sensitive to a phase change in the lipidic bilayer [15,16].
Fig. 2 shows an Arrhenius plot in which the rate
limiting step is the rate of transport of TBT. The graph
is biphasic, showing two different activation energies,
with a break point at 17 8C, as in the case of the
uncouplers.
Since TBT in solution gives rise to the following
equilibrium reactions [18]:
Bu3SnClnH2O0 Cl
Bu3Sn(H2O)

n aq
Bu3Sn(H2O)

n aqH2O
?Bu3Sn(OH)(H2O)n1(aq)H3O

the experimental data suggest that the TBT compound
crosses the mitochondrial membrane as cation
Bu3Sn(H2O)n aq
 through the lipidic bilayer and not by
making use of a physiological carrier.
This behaviour is an essential point in support of our
hypothesis regarding the prevailing TBT neurotoxicity.
In fact, our hypothesis, which is based on the presence in
the nerve cells of the highest potential, which is the
driving force for Bu3Sn(H2O)n aq
 uptake [14], needs to
be clarified with regard to the transport mechanism of
TBT through the membrane.
The transport can occur by means of two possible
mechanisms:
a) specific carrier (proteic pore);
b) an electrophoretic transport through the lipidic
bilayer.
As an explanation of neurotoxicity, the mechanism
(a) implies that a specific carrier for Bu3Sn(H2O)n aq

should be present only in the nerve cells. Such a carrier
has never been found, either in the mitochondrial, or in
the cytoplasmic membrane. Furthermore, the biphasic
Fig. 1. The potassium efflux from the matrix of non-respiring mitochondria. The mitochondrial matrix contains 0.1 M potassium. If the
mitochondria (0.2 mg ml1) are resuspended in a medium with a low potassium concentration (medium composition: 0.25 M sucrose, 10 mM Hepes-
Mops pH 7.4, 10 mM MgCl2, 100 mM KCl, 2 mM rotenone, 1 g cyclosporin A), a K efflux occurs, providing the presence of valinomycin (Val) (2
nmol mg1 protein), the potassium carrier (a). The K efflux is very limited since the K extrusion gives rise to an oppositive force: i.e. the negative-
inside potential (a). A massive K efflux occurs only if a positive counterion, e.g. Ca2, (by means of the physiological carrier), or H (by means of
an uncoupler, FCCP), enters the mitochondria (b). In conditions of an excess of valinomycin (1 nmol mg1 protein), the rate of K efflux indicates
the rate of TBT transport (the initial rate is the slope of the straight line K concentration vs. time, see the dotted line), when 2 mM TBT (chloride)
is added (b). O, mobile carriers; /, proteic pore.
Fig. 2. Arrhenius plot for the transport of TBT in mitochondria.
Medium composition: 0.25 M sucrose, 10 mM Hepes-Mops pH 7.4, 10
mM MgCl2, 100 mM KCl, 2 mM rotenone, 1 g cyclosporin A. To the
medium (4 ml) containing the mitochondria, (0.2 mg ml1) and the
excess valinomycin (1 nmol mg1 protein), 2 mM TBT (chloride) was
added and the (initial) rate of K efflux was measured at different
temperatures. The experimental points are the mean value obtained
from five replicative measurements.
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behaviour of the Arrhenius plot excludes its presence in
mitochondria and, in any case, it is difficult to justify the
presence of a carrier for Bu3Sn(H2O)n aq
 , which is not a
physiological compound.
The electrophoretic transport mechanism (b) occurs
through the lipidic bilayer which is the same in all
biological membranes. In this case, the transport
mechanism has no need of the presence of a carrier (a
proteic pore) specific for a non-physiological com-
pound.
Therefore our experimental data, are in agreement
with a transport mechanism which is sensitive to the
condition of the lipidic bilayer (mechanism b), and they
are, therefore, indispensable in support of a character-
isation of the neurotoxicity of TBT compounds.
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